Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER_GOV 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1

Conditions

Breast Neoplasms 186HER2-positive Breast Cancer 18Neoplasm Metastasis 6Inflammatory Breast Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasms 4Prostatic Neoplasms 3Pathologic Complete Response 3Pancreatic Neoplasms 3HER2-positive Early Breast Cancer 3Endometrial Neoplasms 3Breast Neoplasms, Male 3Anatomic Stage I Breast Cancer AJCC v8 3Stomach Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Locally Advanced Breast Cancer 2Hematologic Neoplasms 2HER2-positive Metastatic Breast Cancer 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Ductal, Breast 2Breast Diseases 2Brain Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1

Interventions

Trastuzumab 5Carboplatin 5Docetaxel 4pertuzumab 3Paclitaxel 3Cyclophosphamide 3pembrolizumab 2Epirubicin 2Doxorubicin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1taxane 1talazoparib 1sarilumab 1pyrotinib 1pirarubicin 1pexidartinib 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1durvalumab 1dostarlimab 1cemiplimab 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pathologic Complete Response × pertuzumab × Breast × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡